THE Federal Government has approved the Pharmaceutical Benefits Scheme listing of Trulicity (dulaglutide) for the treatment of type 2 diabetes.
Trulicity is a glucacon-like peptide (GLP-1) receptor agonist and is available on the PBS from 01 Jun as an Authority Required (streamlined) script for use in combination with metformin (dual therapy) or metformin and a sulfonylurea (triple therapy).
Trulicity is available as a ready-to-use single-use prefilled auto injector pen and is administered on a once weekly basis.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jun 18
